Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Chiesi, Eli Lilly, Johnson & Johnson, Protalix, Sanofi, Ultragenyx, Unicycive.

Biopharma happenings, including deals and partnerships, and other news in brief: Alps, Amgen, Astrazeneca, Bayer, IO Biotech, Kyowa, Moderna, Poxel, Recordati, Regeneron, Samsung Bioepsis.

Clinical updates, including data readouts and publications: Jyong, Quince, Tonix.

Biopharmas raising money in public or private financings, including: Agomab, Altimmune, ALX, Biomarin, Coya, Lexicon, Promis, Spyglass, Vaxcyte.

New hires and promotions in the biopharma industry, including: Immunocore, Merz, Pharmnovo.

The U.S. FDA is now accepting requests from biopharma companies to participate in its new Precheck pilot program, which is intended to make it faster and easier for companies to relocate their prescription drug manufacturing to the U.S.

Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.